SPRB Stock Forecast: Spruce Biosciences, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Spruce Biosciences, Inc. is $143. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 10 of 100 as at 18 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Spruce Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (49): Sales and profits are climbing, and climbing faster than before.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SPRB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SPRB, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | Citizens | Reiterates | Market Outperform | $144 |
| 17 Sept 2026 | Lake Street | Initiates | Buy | $149 |
| 17 Aug 2026 | Guggenheim | Maintains | Buy | $123 → $104 |
| 13 Aug 2026 | Citizens | Maintains | Market Outperform | $150 → $144 |
| 13 July 2026 | B. Riley Securities | Initiates | Buy | $160 |
| 16 June 2026 | Guggenheim | Initiates | Buy | — |
| 9 June 2026 | Jones Trading | Initiates | Buy | — |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 May 2026 | Citizens | Maintains | Market Outperform | — |
| 27 Apr 2026 | Craig-Hallum | Initiates | Buy | — |
| 10 Mar 2026 | Citizens | Maintains | Market Outperform | — |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Dec 2025 | Oppenheimer | Initiates | Outperform | — |
| 22 Dec 2025 | HC Wainwright & Co. | Assumes | Buy | $220 |
| 3 Dec 2025 | Leerink Partners | Upgrade | Outperform | — |
| 11 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 28 Oct 2025 | JMP Securities | Upgrade | Market Outperform | — |
| 21 Oct 2025 | Leerink Partners | Maintains | Market Perform | — |
| 16 Apr 2025 | RBC Capital | Maintains | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SPRB.
This page is one stock. Monday covers all of them.
SPRB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SPRB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.8×
- EV / EBITDA
- —
Cheaper than 49% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −187.4%
- Return on assets
- −54.2%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Spruce Biosciences, Inc. has a market value of $116.4M and an enterprise value of $37.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$51.4M.
Free cash flow in the twelve months to 30 June 2026: −$42.8M.
forward P/E: 10.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Spruce Biosciences, Inc. employs 25 people.
Data provided by Twelve Data
SPRB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SPRB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Spruce Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SPRB
What is the SPRB stock price forecast for 2026-2027?
The median 12-month analyst price target for Spruce Biosciences, Inc. is $143, with estimates ranging from $104 to $230. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SPRB stock a buy right now?
Of the 9 analysts covering Spruce Biosciences, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spruce Biosciences, Inc. 10 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SPRB?
As at 18 Nov 2026, Spruce Biosciences, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (49 of 100).
Will SPRB stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts is $143, and Ticker Nerd's factor model ranks Spruce Biosciences, Inc. 10 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SPRB stock forecast for 2030?
No analyst covering Spruce Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $104 to $230 over the next 12 months.
What does Spruce Biosciences, Inc. do?
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical need. Its current portfolio centers on enzyme replacement and small-molecule programs designed to address serious diseases where treatment options are limited or inadequate.
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical need. Its current portfolio centers on enzyme replacement and small-molecule programs designed to address serious diseases where treatment options are limited or inadequate. The company’s work includes therapies for conditions such as Sanfilippo Syndrome Type B and congenital adrenal hyperplasia, reflecting its emphasis on targeted medicines for underserved patient populations. Spruce Biosciences, Inc. operates in the biotechnology sector and participates in the broader rare-disease market, where specialized clinical development and regulatory expertise are essential to bringing therapies to patients. Headquartered in South San Francisco, California, the company is positioned as a development-stage biopharmaceutical business concentrated on advancing precision treatments for complex disorders.
CEO Dr. Javier Szwarcberg M.D., M.P.H. · 25 employees · United States · https://sprucebio.com